Patent details

Basic Information

Publication number:

EP3212668

PCT Application Number:

US2015058389

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP157912130

PCT Publication Number:

WO2016070089

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

French Title of Invention:

ANTICORPS ANTI-CS1 ET CONJUGUÉS ANTICORPS-MÉDICAMENT

German Title of Invention:

ANTI-CS1-ANTIKÖRPER UND ANTIKÖRPERWIRKSTOFFKONJUGATE

SPC Number:

Dates

Filing date:

30/10/2015

Grant date:

14/10/2020

EP Publication Date:

06/09/2017

PCT Publication Date:

06/05/2016

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

14/10/2020

EP B1 Publication Date:

14/10/2020

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

30/10/2020

Expiration date:

30/10/2035

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

07/10/2020

 

 

Name:

AbbVie Biotherapeutics Inc.

Address:

1500 Seaport Boulevard, Redwood City, CA 94063, United States (US)

Inventor

1

Name:

NAUMOVSKI, Louie

Address:

United States (US)

2

Name:

GISH, Kurt C.

Address:

United States (US)

3

Name:

KIM, Han K.

Address:

United States (US)

Priority

Priority Number:

201462073824 P

Priority Date:

31/10/2014

Priority Country:

United States (US)

Classification

IPC classification:

A61K 31/00; A61P 35/00; C07K 16/28;

Publication

European Patent Bulletin

Issue number:

202042

Publication date:

14/10/2020

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages